Form 4: Myriad Genetics Executive Acquires Shares and Disposes of Shares for Tax Obligations
SEC Form 4 Filing
Mark Verratti, Chief Commercial Officer of Myriad Genetics, acquired shares through restricted stock units and disposed of shares to cover tax obligations.
Summary
- On March 14, 2024, Mark Verratti, the Chief Commercial Officer of Myriad Genetics, acquired 58,631 shares of common stock through time-based restricted stock units at a price of $0.
- These restricted stock units vest in three equal annual installments starting on the first anniversary of the grant date.
- On March 15, 2024, Verratti disposed of 3,686 shares at $21.16 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.
- Following these transactions, Verratti directly owns 304,684 shares of Myriad Genetics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine insider transactions related to stock options and tax obligations.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Key Dates
| Date | Description |
|---|---|
| 03/14/2024 | Mark Verratti acquired 58,631 shares of Myriad Genetics common stock through restricted stock units. |
| 03/15/2024 | Mark Verratti disposed of 3,686 shares of Myriad Genetics common stock to cover tax obligations at $21.16 per share. |
| 03/18/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.